- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Overview
This bill would require the HHS Secretary to maintain strict safety protocols (a Risk Evaluation and Mitigation Strategy) for mifepristone, the drug used in medication abortion, and would reverse recent FDA decisions that loosened those protections.
Law Today
Mifepristone (a medication used in medication abortion) is currently regulated under a risk evaluation and mitigation strategy (REMS) approved by the FDA. The bill references a previously approved strategy that the bill seeks to restore.
If Passed
This bill would require the Secretary of Health and Human Services to reinstate a prior risk evaluation and mitigation strategy for mifepristone that was in effect before recent changes. This would likely restore stricter requirements around how the drug is distributed, who can prescribe it, and what safety monitoring is required—making medication abortion more difficult to access and potentially less available in some areas.
AI-generated from the bill text — verify against the official text.
Should I support this?
- Strongly Oppose
- Likely Oppose
- Neutral
- This billLikely Support
- Strongly Support
Likely Support
From a Christian perspective that values the sanctity of life, this bill would help protect unborn life by making abortion medication harder to access. However, the practical and ethical effects on women's health and autonomy are significant trade-offs that Christian families may weigh differently depending on their broader convictions about law, compassion, and competing goods.
AI assessment using F3’s editorial criteria — faith, family, and freedom. This is F3’s policy judgment; verify the provisions in the official bill text.
Likely supporters & opponents
Likely support
- pro-life advocacy organizations — Stricter safety protocols for abortion drugs protect women's health and reduce access to a method they believe is harmful.
- religious groups opposing abortion — Restoring safeguards aligns with their conviction that abortion should be discouraged and made less accessible.
Likely opposition
- abortion-rights advocacy organizations — Reimposing stricter REMS requirements restricts women's access to a safe, FDA-approved medication and is based on outdated safety concerns.
- medical associations and reproductive-health providers — Current REMS requirements are already sufficient for safety, and stricter rules create unnecessary barriers to care and contradict medical evidence.
AI-inferred typical positions based on the bill’s substance — general stakeholder categories, not confirmed endorsements.
Official summary
A bill to require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Sponsors
- Josh Hawley (R)
Status timeline
- 2025-05-06Read twice and referred to the Committee on Health, Education, Labor, and Pensions.S
H = House · S = Senate · A = Assembly